Developer docs
API playgroundTry for free, no card

Search company profiles

Scopio Labs

Full company profile

uuid00007l9

Namestring
Scopio Labs
Legal namestring
Scopio Labs Ltd.
Websiteurl
scopiolabs.com
Company typeenum
Private
Founded yearint
2015
Descriptiontext

Scopio Labs Ltd. is an Israeli-headquartered medical technology company founded in 2015 that develops Full-Field Digital Cell Morphology platforms for hematology diagnostics. Its core offering combines proprietary computational photography hardware (X100 and X100HT high-resolution slide scanners that capture entire blood smear and bone marrow aspirate slides at 100x oil-immersion equivalent resolution) with AI-powered decision support software for peripheral blood smear review and bone marrow aspirate analysis. The AI models pre-classify white blood cells into 16+ classes, evaluate red blood cell morphology across 23 parameters, perform platelet estimation, and detect platelet clumps, with clinical validation demonstrating 99.77% agreement with manual microscopy for RBC morphology and 96.29% accuracy for WBC differentials across multicenter studies. The company has accumulated four FDA clearances and two EU IVDR certifications, including a De Novo clearance that established a new regulatory category for digital bone marrow aspirate analysis.

Scopio Labs generates revenue through a hardware-plus-software model: capital sales of X100/X100HT imaging platforms integrated with licensed AI software applications (Full-Field Peripheral Blood Smear Application and Full-Field Bone Marrow Aspirate Application). Distribution is hybrid, combining direct enterprise sales led by a Chief Commercial Officer with global channel partnerships signed with Beckman Coulter Diagnostics (since July 2022) and Siemens Healthineers (since May 2023), both subsequently expanded to cover the bone marrow aspirate product line. The company serves clinical hematology laboratories, multi-site hospital networks, academic medical centers, and specialized hematopathology departments across the United States, United Kingdom, continental Europe, and Israel, with named customers including Mount Sinai, PathGroup, Tel Aviv Sourasky Medical Center, Ghent University Hospital, and SYNLAB-affiliated reference laboratories. A Complete Blood Morphology analyzer offering fully autonomous morphology analysis is in development. The company also operates a parallel veterinary sub-brand, ScopioVet, in the US, UK, and Ireland.

Short descriptiontext

Scopio Labs develops Full-Field Digital Cell Morphology imaging platforms and AI-powered decision support software for clinical hematology laboratories, serving hospitals, academic medical centers, and reference laboratories globally through direct sales and channel partnerships with Beckman Coulter Diagnostics and Siemens Healthineers.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
101–250
akta.pro rankint
HeadquartersTel Aviv, Israel
HQ citystring
Tel Aviv
HQ countrystring
Israel
HQ regionstring
Middle East
Markets served

Serves global market

Offices3 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
digital cell morphology, hematology diagnostics, AI microscopy imaging, peripheral blood smear, bone marrow aspirate
Industry3 codes
PRIMARYHLAGAIAE
Microscopy, Imaging & Flow Cytometry Instruments
SECONDARYHDAAAEAH
Medical Imaging AI
SECONDARYHLACAMAB
Anatomic Pathology LIS & Digital Pathology Workflow
Healthcare & Life Sciences/Digital Health & Health IT/Laboratory Information Systems (LIS/LIMS) & Pathology Informatics
NAICS code1 code
  • Analytical Laboratory Instrument Manufacturing334516
SIC code2 codes
  • Laboratory Analytical Instruments3826
  • Optical Instruments & Lenses3827
Product category
Digital Hematology Imaging Systems
GTM motion3 records

Each record includes

Type, Description, Source

Revenue model2 records
1Digital Morphology Platforms (Hardware + Software)
TypeHardware Sales
Description

Sale of X100 and X100HT digital slide-scanning devices integrated with AI-powered software applications for peripheral blood smear and bone marrow aspirate analysis. Platforms are sold to hematology labs, hospitals, and laboratory networks globally through direct sales and channel partners.

scopiolabs.com
2Software Applications (Subscriptions/Licensing)
TypeSubscription Recurring
Description

AI-powered decision support software applications (Full-Field Peripheral Blood Smear Application, Full-Field Bone Marrow Aspirate Application) licensed for use on Scopio's X100/X100HT platforms. CBM analyzer under development. Revenue generated through software licensing and application fees integrated with hardware platform sales.

scopiolabs.com
Marketing channels9 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels3 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components1 value
Technology or R&D
Pricing details1 tier
1X100 and X100HT platforms with integrated software applications
ModelOtherBilling cadenceMulti-year contract
Notes

No public pricing available; products are sold through enterprise direct sales and global distribution partners (Beckman Coulter, Siemens Healthineers). Quote-based sales model typical for medical device platforms targeting hospital and laboratory networks.

scopiolabs.com
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 record
1ScopioVet
Description

Digital cytology system for veterinary professionals, offered in the United States, United Kingdom and Ireland.

scopiolabs.com
Core offering1 text field

Scopio Labs develops and sells Full-Field Digital Cell Morphology imaging platforms (X100 and X100HT) that capture entire peripheral blood smear and bone marrow aspirate slides at 100x magnification. The hardware platforms run AI-powered applications including the Full-Field Peripheral Blood Smear Application, Full-Field Bone Marrow Aspirate Application, and the in-development Complete Blood Morphology (CBM) analyzer that provide automated cell classification, morphological analysis, and remote review for clinical hematology laboratories.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 10 values shown
  • 60% reduction in peripheral blood smear review turnaround time
+9 more records
Product overview1 text field

Scopio Labs offers a platform-based architecture centered on the X100 and X100HT Full-Field Digital Cell Morphology imaging platforms, which serve as the hardware foundation for a suite of AI-powered applications. The core applications include the Full-Field Peripheral Blood Smear Application (FDA-cleared and CE-marked) for digital PBS review with WBC differential, RBC morphology, and platelet estimation, and the Full-Field Bone Marrow Aspirate Application (CE-marked, FDA De Novo cleared) for comprehensive bone marrow analysis. The Complete Blood Morphology (CBM) Analyzer, currently under development, represents the next-generation autonomous morphology solution built on the same Full-Field technology platform, designed to deliver fully automated results from scan to final report.

Product and service4 records
1X100 and X100HT Full-Field Digital Cell Morphology Imaging Platforms
CategoryDigital Microscopy Hardware
Description

Hardware imaging platforms that capture full-field digital images of peripheral blood smears and bone marrow aspirates at 100x magnification resolution. The X100 processes up to 15 samples/hour with a 3-slide tray; the X100HT processes up to 40 samples/hour with 30-slide capacity. Both feature computational photography for high-resolution imaging and embedded AI decision support, sold to clinical hematology laboratories and hospital networks globally.

2Full-Field Peripheral Blood Smear (FF-PBS) Application
CategoryClinical Diagnostics Software
Description

FDA-cleared and CE-marked software application for digital peripheral blood smear review. Features adaptive monolayer identification, WBC pre-classification into 16 classes, RBC morphology evaluation across 23 parameters, and platelet estimation with clump detection. Reduces PBS review turnaround time by 60% and enables remote review over secure hospital networks.

3Full-Field Bone Marrow Aspirate (FF-BMA) Application
CategoryClinical Diagnostics Software
Description

World's first complete digital workflow for bone marrow aspirate scanning and analysis. CE-marked and FDA De Novo cleared. Combines high-resolution Full-Field imaging with AI-powered decision support for blast cell estimation, plasma cell estimation, M:E ratio calculation, and bone marrow smear quality assessment, enabling remote review of entire smears at 100x.

4Complete Blood Morphology (CBM) Analyzer
CategoryClinical Diagnostics Software
Description

Next-generation autonomous blood morphology analyzer that fully automates peripheral blood smear analysis from scan to final report. Built on Scopio's proprietary Full-Field technology platform with advanced computational imaging and deep learning AI. Analyzes thousands of cells (10x more than the 100-200 cell manual standard of care) for fully autonomous, standardized morphology analysis.

Scale indicator16 records

Each record includes

Type, Value, Description, Source

Partnership2 partners
Strategic tierCoreTypeChannel Partner/ Reseller/ DistributorAnnounced on2023-05-08
Description

Global distribution agreement signed May 2023 granting Siemens Healthineers rights to distribute Scopio's X100 and X100HT digital morphology platforms with Full-Field Peripheral Blood Smear Application, complementing Siemens Healthineers' existing hematology portfolio including Atellica HEMA 570/580 Analyzers. Expanded in January 2025 to include FF-BMA Application globally. Partnership supports Siemens Healthineers' goal of providing automated and digitized solutions for hematology workflow transformation.

2Beckman Coulter Diagnostics
Strategic tierCoreTypeChannel Partner/ Reseller/ DistributorAnnounced on2022-07-20
Description

Worldwide partnership since July 2022 to accelerate adoption of Scopio's next-generation peripheral blood smear platforms. Expanded in September 2024 to include global distribution of the Full-Field Bone Marrow Aspirate (FF-BMA) Application. Beckman Coulter, part of Danaher Corporation (NYSE: DHR), is a global leader in clinical diagnostics with 80+ years of experience. In 2023, Beckman Coulter announced an end-to-end automated hematology solution connecting its DxH 900 Workcell and DxH Slidemaker Stainer II with the Scopio X100HT high-throughput digital cell morphology platform.

scopiolabs.com
Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeBroad incumbent
Description

Global leader in hematology analyzers and the dominant supplier of CBC/diff instrumentation; competes with Scopio's morphology workflow through integrated automated digital cell imaging (DI-60) and is the most direct incumbent competitor in clinical hematology labs.

TypeDirect peer
Description

Swedish-based digital morphology company providing automated WBC differential and RBC morphology on digital slide images; offers the most directly overlapping digital cell morphology product to Scopio's X100/X100HT and is the closest direct peer in hematology lab digitization.

3Beckman Coulter Diagnostics (Danaher)
TypeBroad incumbent
Description

Major hematology analyzer vendor and Scopio's global distribution partner; offers DxH series analyzers plus its own DxH Slidemaker Stainer II integrated with Scopio X100HT, making it both a critical channel and a strategic incumbent that could internalize morphology.

TypeBroad incumbent
Description

Global diagnostics company distributing the Atellica HEMA 570/580 analyzers and Scopio's X100/X100HT; as a partner and broader hematology incumbent, it is both the route to market and a potential competitor with internal morphology ambitions.

TypeBroad incumbent
Description

Major clinical diagnostics incumbent with hematology and digital pathology offerings; competes for hospital lab budgets that Scopio targets and is a likely reference point for hospital procurement evaluations.

TypeBroad incumbent
Description

Large Chinese-origin medical device company with a growing hematology analyzer portfolio; competes on price-sensitive hematology lab deals globally and is a credible alternative for cost-conscious hospital networks.

TypeBroad incumbent
Description

Hematology and clinical chemistry analyzer vendor with growing digital morphology ambitions; competes for the same mid-sized hospital and reference lab morphology budgets as Scopio.

TypeEmerging player
Description

Emerging digital pathology vendor offering whole-slide imaging systems for remote review; partial overlap with Scopio's digital slide imaging and remote consultation value proposition in smaller hospital settings.

TypeEmerging player
Description

Digital pathology scanning vendor expanding into hematology and remote review use cases; adjacent competitor targeting budget-constrained hospital digital pathology deployments.

TypeOthers
Description

Diagnostic and women's health company with a clinical diagnostics franchise that occasionally overlaps with cytology/hematology workflows; relevant adjacent peer for hospital capital allocation decisions.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers7 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

Integration2 records

Each record includes

Title, Type, Description, Source

AI capability7 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature7 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles9 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
Compliance7 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds8 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors11 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Scopio Labs

Digital Hematology Imaging Systemsscopiolabs.com

Scopio Labs develops Full-Field Digital Cell Morphology imaging platforms and AI-powered decision support software for clinical hematology laboratories, serving hospitals, academic medical centers, and reference laboratories globally through direct sales and channel partnerships with Beckman Coulter Diagnostics and Siemens Healthineers.

What Scopio Labs does

Scopio Labs Ltd. is an Israeli-headquartered medical technology company founded in 2015 that develops Full-Field Digital Cell Morphology platforms for hematology diagnostics. Its core offering combines proprietary computational photography hardware (X100 and X100HT high-resolution slide scanners that capture entire blood smear and bone marrow aspirate slides at 100x oil-immersion equivalent resolution) with AI-powered decision support software for peripheral blood smear review and bone marrow aspirate analysis. The AI models pre-classify white blood cells into 16+ classes, evaluate red blood cell morphology across 23 parameters, perform platelet estimation, and detect platelet clumps, with clinical validation demonstrating 99.77% agreement with manual microscopy for RBC morphology and 96.29% accuracy for WBC differentials across multicenter studies. The company has accumulated four FDA clearances and two EU IVDR certifications, including a De Novo clearance that established a new regulatory category for digital bone marrow aspirate analysis.

Scopio Labs generates revenue through a hardware-plus-software model: capital sales of X100/X100HT imaging platforms integrated with licensed AI software applications (Full-Field Peripheral Blood Smear Application and Full-Field Bone Marrow Aspirate Application). Distribution is hybrid, combining direct enterprise sales led by a Chief Commercial Officer with global channel partnerships signed with Beckman Coulter Diagnostics (since July 2022) and Siemens Healthineers (since May 2023), both subsequently expanded to cover the bone marrow aspirate product line. The company serves clinical hematology laboratories, multi-site hospital networks, academic medical centers, and specialized hematopathology departments across the United States, United Kingdom, continental Europe, and Israel, with named customers including Mount Sinai, PathGroup, Tel Aviv Sourasky Medical Center, Ghent University Hospital, and SYNLAB-affiliated reference laboratories. A Complete Blood Morphology analyzer offering fully autonomous morphology analysis is in development. The company also operates a parallel veterinary sub-brand, ScopioVet, in the US, UK, and Ireland.

Scopio Labs firmographics

Firmographics
Name
Scopio Labs
Legal name
Scopio Labs Ltd.
Website
https://scopiolabs.com
Company type
Private
Founded year
2015
Operating status
Operating
Headcount range
101–250 employees
Short description
Scopio Labs develops Full-Field Digital Cell Morphology imaging platforms and AI-powered decision support software for clinical hematology laboratories, serving hospitals, academic medical centers, and reference laboratories globally through direct sales and channel partnerships with Beckman Coulter Diagnostics and Siemens Healthineers.
Ownership category
akta.pro rank

Scopio Labs industry classification

Industry
Product category
Digital Hematology Imaging Systems
NAICS
Analytical Laboratory Instrument Manufacturing (334516)
SIC
Laboratory Analytical Instruments (3826), Optical Instruments & Lenses (3827)
akta.pro industry
PRIMARYHLAGAIAE
Microscopy, Imaging & Flow Cytometry Instruments
SECONDARYHDAAAEAH
Medical Imaging AI
SECONDARYHLACAMAB
Anatomic Pathology LIS & Digital Pathology Workflow
Healthcare & Life Sciences/Digital Health & Health IT/Laboratory Information Systems (LIS/LIMS) & Pathology Informatics

Keywords

  • Digital cell morphology
  • Hematology diagnostics
  • AI microscopy imaging
  • Peripheral blood smear
  • Bone marrow aspirate

Where Scopio Labs is headquartered

Location

Headquarters

HQ city
Tel Aviv
HQ country
Israel
HQ region
Middle East

Offices3 records

Markets served

Scopio Labs business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D

Revenue model

  1. Digital Morphology Platforms (Hardware + Software): Sale of X100 and X100HT digital slide-scanning devices integrated with AI-powered software applications for peripheral blood smear and bone marrow aspirate analysis. Platforms are sold to hematology labs, hospitals, and laboratory networks globally through direct sales and channel partners.
  2. Software Applications (Subscriptions/Licensing): AI-powered decision support software applications (Full-Field Peripheral Blood Smear Application, Full-Field Bone Marrow Aspirate Application) licensed for use on Scopio's X100/X100HT platforms. CBM analyzer under development. Revenue generated through software licensing and application fees integrated with hardware platform sales.

Pricing tiers

ModelBillingPrice
OtherMulti-year contractX100 and X100HT platforms with integrated software applications

Go-to-market motion3 records

Distribution channels3 records

Marketing channels9 records

Scopio Labs product offering

Product offering

Core offering

Scopio Labs develops and sells Full-Field Digital Cell Morphology imaging platforms (X100 and X100HT) that capture entire peripheral blood smear and bone marrow aspirate slides at 100x magnification. The hardware platforms run AI-powered applications including the Full-Field Peripheral Blood Smear Application, Full-Field Bone Marrow Aspirate Application, and the in-development Complete Blood Morphology (CBM) analyzer that provide automated cell classification, morphological analysis, and remote review for clinical hematology laboratories.

Product overview

Scopio Labs offers a platform-based architecture centered on the X100 and X100HT Full-Field Digital Cell Morphology imaging platforms, which serve as the hardware foundation for a suite of AI-powered applications. The core applications include the Full-Field Peripheral Blood Smear Application (FDA-cleared and CE-marked) for digital PBS review with WBC differential, RBC morphology, and platelet estimation, and the Full-Field Bone Marrow Aspirate Application (CE-marked, FDA De Novo cleared) for comprehensive bone marrow analysis. The Complete Blood Morphology (CBM) Analyzer, currently under development, represents the next-generation autonomous morphology solution built on the same Full-Field technology platform, designed to deliver fully automated results from scan to final report.

Differentiator

Problem solved

Functional benefit

Brands

  • ScopioVet: Digital cytology system for veterinary professionals, offered in the United States, United Kingdom and Ireland.

Products and services

  • X100 and X100HT Full-Field Digital Cell Morphology Imaging Platforms Hardware imaging platforms that capture full-field digital images of peripheral blood smears and bone marrow aspirates at 100x magnification resolution. The X100 processes up to 15 samples/hour with a 3-slide tray; the X100HT processes up to 40 samples/hour with 30-slide capacity. Both feature computational photography for high-resolution imaging and embedded AI decision support, sold to clinical hematology laboratories and hospital networks globally.
  • Full-Field Peripheral Blood Smear (FF-PBS) Application FDA-cleared and CE-marked software application for digital peripheral blood smear review. Features adaptive monolayer identification, WBC pre-classification into 16 classes, RBC morphology evaluation across 23 parameters, and platelet estimation with clump detection. Reduces PBS review turnaround time by 60% and enables remote review over secure hospital networks.
  • Full-Field Bone Marrow Aspirate (FF-BMA) Application World's first complete digital workflow for bone marrow aspirate scanning and analysis. CE-marked and FDA De Novo cleared. Combines high-resolution Full-Field imaging with AI-powered decision support for blast cell estimation, plasma cell estimation, M:E ratio calculation, and bone marrow smear quality assessment, enabling remote review of entire smears at 100x.
  • Complete Blood Morphology (CBM) Analyzer Next-generation autonomous blood morphology analyzer that fully automates peripheral blood smear analysis from scan to final report. Built on Scopio's proprietary Full-Field technology platform with advanced computational imaging and deep learning AI. Analyzes thousands of cells (10x more than the 100-200 cell manual standard of care) for fully autonomous, standardized morphology analysis.

Quantifiable outcome

  • 60% reduction in peripheral blood smear review turnaround time
  • +9 more outcomes

Companies that use Scopio Labs

Customer profile

Named customers7 records

Segments3 records

Ideal customer profiles3 records

Scopio Labs technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Integration2 records

AI capability7 records

Feature7 records

Scopio Labs partnerships and signals

Strategic signal

Partnerships

Two partnerships are on record, tiered core.

  • Siemens HealthineerscoreChannel Partner/ Reseller/ Distributor · 8 May 2023Global distribution agreement signed May 2023 granting Siemens Healthineers rights to distribute Scopio's X100 and X100HT digital morphology platforms with Full-Field Peripheral Blood Smear Application, complementing Siemens Healthineers' existing hematology portfolio including Atellica HEMA 570/580 Analyzers. Expanded in January 2025 to include FF-BMA Application globally. Partnership supports Siemens Healthineers' goal of providing automated and digitized solutions for hematology workflow transformation.
  • Beckman Coulter DiagnosticscoreChannel Partner/ Reseller/ Distributor · 20 July 2022Worldwide partnership since July 2022 to accelerate adoption of Scopio's next-generation peripheral blood smear platforms. Expanded in September 2024 to include global distribution of the Full-Field Bone Marrow Aspirate (FF-BMA) Application. Beckman Coulter, part of Danaher Corporation (NYSE: DHR), is a global leader in clinical diagnostics with 80+ years of experience. In 2023, Beckman Coulter announced an end-to-end automated hematology solution connecting its DxH 900 Workcell and DxH Slidemaker Stainer II with the Scopio X100HT high-throughput digital cell morphology platform.

Scale indicators16 records

Recent moves6 records

Expansion highlights6 records

Scopio Labs competitors and assessment

Company assessment

Broad incumbents

  • Sysmex: Global leader in hematology analyzers and the dominant supplier of CBC/diff instrumentation; competes with Scopio's morphology workflow through integrated automated digital cell imaging (DI-60) and is the most direct incumbent competitor in clinical hematology labs.
  • Beckman Coulter Diagnostics (Danaher): Major hematology analyzer vendor and Scopio's global distribution partner; offers DxH series analyzers plus its own DxH Slidemaker Stainer II integrated with Scopio X100HT, making it both a critical channel and a strategic incumbent that could internalize morphology.
  • Siemens Healthineers: Global diagnostics company distributing the Atellica HEMA 570/580 analyzers and Scopio's X100/X100HT; as a partner and broader hematology incumbent, it is both the route to market and a potential competitor with internal morphology ambitions.
  • Roche Diagnostics: Major clinical diagnostics incumbent with hematology and digital pathology offerings; competes for hospital lab budgets that Scopio targets and is a likely reference point for hospital procurement evaluations.
  • Mindray: Large Chinese-origin medical device company with a growing hematology analyzer portfolio; competes on price-sensitive hematology lab deals globally and is a credible alternative for cost-conscious hospital networks.
  • HORIBA Medical: Hematology and clinical chemistry analyzer vendor with growing digital morphology ambitions; competes for the same mid-sized hospital and reference lab morphology budgets as Scopio.

Direct peers

  • CellaVision: Swedish-based digital morphology company providing automated WBC differential and RBC morphology on digital slide images; offers the most directly overlapping digital cell morphology product to Scopio's X100/X100HT and is the closest direct peer in hematology lab digitization.

Emerging players

  • Mikroscan Technologies: Emerging digital pathology vendor offering whole-slide imaging systems for remote review; partial overlap with Scopio's digital slide imaging and remote consultation value proposition in smaller hospital settings.
  • OptraScan: Digital pathology scanning vendor expanding into hematology and remote review use cases; adjacent competitor targeting budget-constrained hospital digital pathology deployments.

Others

  • Hologic: Diagnostic and women's health company with a clinical diagnostics franchise that occasionally overlaps with cytology/hematology workflows; relevant adjacent peer for hospital capital allocation decisions.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

Scopio Labs social profiles

Digital presence

Scopio Labs compliance and trust

Trust signal

Compliance7 records

Scopio Labs financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Scopio Labs leadership team

Management profile

Number of profiles

Profiles9 records

Scopio Labs funding detail

Funding detail

Funding overview

Funding rounds8 records

Investors11 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Scopio Labs M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Scopio Labs

What does Scopio Labs do?

Scopio Labs develops and sells Full-Field Digital Cell Morphology imaging platforms (X100 and X100HT) that capture entire peripheral blood smear and bone marrow aspirate slides at 100x magnification. The hardware platforms run AI-powered applications including the Full-Field Peripheral Blood Smear Application, Full-Field Bone Marrow Aspirate Application, and the in-development Complete Blood Morphology (CBM) analyzer that provide automated cell classification, morphological analysis, and remote review for clinical hematology laboratories.

Is Scopio Labs a public or private company?

Scopio Labs is a private company. It is classified as venture growth investor backed and is currently operating.

When was Scopio Labs founded?

Scopio Labs was founded in 2015. It employs 101 to 250 people.

Where is Scopio Labs based?

Scopio Labs is headquartered in Tel Aviv, Israel, in the Middle East region.

How does Scopio Labs make money?

Two revenue lines are on record. Digital Morphology Platforms (Hardware + Software) is the primary driver. The others are software Applications (Subscriptions/Licensing).

Who are Scopio Labs's main competitors?

Broad incumbents on record are Sysmex, Beckman Coulter Diagnostics (Danaher), Siemens Healthineers, Roche Diagnostics, Mindray and HORIBA Medical. CellaVision is listed as a direct peer. Emerging players are Mikroscan Technologies and OptraScan. Hologic is listed as an others.

Does Scopio Labs have an API?

No public API is recorded for Scopio Labs.

What industry is Scopio Labs in?

Scopio Labs's product category is Digital Hematology Imaging Systems. Its primary akta.pro industry code is HLAGAIAE, Microscopy, Imaging & Flow Cytometry Instruments, with a secondary code of HDAAAEAH, Medical Imaging AI. Its NAICS code is 334516 and its SIC code is 3826.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
PR NewswireScopio Labs Secures EU IVDR Certification for the Industry-Only Full-Field Digital Bone Marrow ApplicationScopio Labs announced it has achieved IVDR (In Vitro Diagnostic Regulation) certification for its Full-Field Bone Marrow Aspirate Application, covering both the X100 and X100HT platforms, making it the only provider of high-throughput Full-Field digital imaging at 100x for bone marrow diagnostics in the European Union. The certification establishes a unified, regulated digital workflow for hematology labs across the EU and follows the company's recent IVDR approval for its Full-Field Peripheral Blood Smear Application with RBC AI-powered decision support. Coinciding with this regulatory milestone, Scopio launched a new BMA software version featuring DICOM-enabled image export, Advanced Analysis Area Management, and extended color compatibility configurations.openPR.comGlobal Drivers Analysis: The Rapid Evolution of the Digital Cell Morphology System MarketThe digital cell morphology system market is projected to reach $3.49 billion by 2030, growing at a compound annual growth rate of 10.6%, driven by AI integration, automation in diagnostics, and increased biotechnology investments. In August 2025, France-based AB Science S.A. partnered with US-based Scopio Labs Inc. to integrate AI-powered digital blood-cell analysis into AB Science's diagnostic services. In July 2025, Israel-based Scopio Labs Ltd. launched its complete blood morphology analyzer, an AI-based image analyzer that can process up to ten times more cells than traditional methods for peripheral blood smear reviews.PR NewswireScopio Labs Achieves EU IVDR Certification for AI-Powered Full-Field Digital Morphology PlatformsScopio Labs has achieved IVDR certification from BSI, a major regulatory milestone that clears the path for its AI-driven digital morphology platforms (X100 and X100HT) in the European Union. The certification covers the company's QMS and full technical documentation, including its Full-Field Peripheral Blood Smear Application with RBC AI-powered decision support. This achievement builds on the company's recent FDA clearance and solidifies Scopio's regulatory position as it expands into key international markets.NucampHow AI Is Helping Healthcare Companies in Israel Cut Costs and Improve EfficiencyIsraeli healthcare organizations are deploying AI across medical imaging, pathology, remote monitoring, and clinical automation, with documented gains including ~27% faster time-to-diagnosis, ~37% increase in lab productivity, and 1–2 fewer hospital days per patient across 40,000 patients and 80 hospitals. Israeli AI health firms including Aidoc, Ibex, Scopio, Biobeat, and MedAware have demonstrated measurable ROI—MedAware estimates $5.5–$8.5 saved per $1 spent and flagged 10,668 potential medication errors—while tools from MyndYou, EchoCare, VITALERTER, and Diagnostic Robotics address remote monitoring, elder care, and population health. Israel's healthcare AI ecosystem, backed by over 1,500 active startups, interoperable HMO data systems, and hospital-startup partnerships, is shifting from pilots to scaled deployments, though the stalled National AI Program and regulatory frameworks on privacy and bias remain under development.Pulse 2.0Scopio Labs: $10 Million More Raised For Automating Blood MorphologyScopio Labs has launched its AI-based Complete Blood Morphology (CBM) analyzer, designed to automate the traditionally manual peripheral blood smear review process by analyzing ten times more cells than current methods. Viola Growth has invested an additional $10 million into Scopio Labs, bringing its Series D funding to $52 million total, to support the CBM's market launch. The CBM analyzer, which holds CE-marked and FDA-cleared status, aims to address the global laboratory staffing crisis while enabling fully automated hematology diagnostics from CBC to final result.Clinical Lab ProductsScopio Labs Unveils AI-Powered Solution to Fully Automate Blood MorphologyScopio Labs announced its Complete Blood Morphology (CBM) analyzer, which uses AI and Full-Field technology to fully automate blood smear analysis, backed by a $10 million Series D extension from Viola Growth. The system aims to improve efficiency and standardization in hematology labs by analyzing ten times more cells than current manual methods and is set to be showcased at ADLM 2025.CTechScopio Labs extends Series D with additional $10 millionScopio Labs raised an additional $10 million in Series D funding, bringing the round to $52 million. The funds will accelerate its CBM analyzer, an AI-powered system that automates peripheral blood smear review. The analyzer is still under development and will be presented at ADLM 2025.PR NewswireScopio Labs Unveils First-of-Its-Kind AI-Powered Solution to Fully Automate Blood MorphologyScopio Labs unveiled its Complete Blood Morphology (CBM) analyzer, an AI-powered system that automates blood cell morphology review. The company raised $10 million from Viola Growth, bringing total Series D funding to $52 million. CBM is under development and not available for in vitro diagnostic use.AiinlabcoatThe Surprising New Way to Diagnose Pneumonia FasterThe article aggregates multiple developments in AI-driven healthcare, including XP Health securing $33.2 million in Series B funding to expand its affordable vision care platform and Beckman Coulter Diagnostics partnering with Scopio Labs to launch a digital bone marrow imaging solution. Other reported events involve Neuralink receiving FDA breakthrough designation for its brain implant and various other companies raising capital or launching new diagnostic tools.